Predicting I-avidity of Metastases from Differentiated Thyroid Cancer Using F-FDG PET/CT in Postoperative Patients with Elevated Thyroglobulin

Overview

Journal Sci Rep

Specialty Science

Date 2018 Mar 14

PMID 29531251

Citations 10

Authors

Min Liu

Lingxiao Cheng

Yuchen Jin

Maomei Ruan

Shiwei Sheng

Libo Chen

Affiliations

Soon will be listed here.

Abstract

The quantitative relationship between iodine and glucose metabolism in metastases from differentiated thyroid cancer (DTC) remains unknown. Aim of the prospective study was to establish the value of F-FDG PET/CT in predicting I-avidity of metastases from DTC before the first radioiodine therapy. A total of 121 postoperative DTC patients with elevated stimulated serum thyroglobulin (ssTg) who underwent I adjuvant therapy or therapy after F-FDG PET/CT scan were enrolled. The Receiver operating characteristic curve was established to create an optimal cut-off point and evaluate the value of SUVmax for predicting I-avidity. In our study, the median SUVmax in I-nonavid metastatic target lesions was also significantly higher than that in I-avid metastatic target lesions (5.37 vs. 3.30; P = 0.000). At a cut-off value of 4.0 in SUVmax, the area under curve was 0.62 with the sensitivity, specificity, positive predictive value and negative predictive value of 75.3%, 56.7%, 76.1%, and 54.8%, respectively. These results suggest that F-FDG PET/CT may be of great value in identifying metastases in postoperative DTC patients with elevated ssTg before I administration, leading to an improved management of disease. F-FDG positive metastatic DTC with SUVmax of greater than 4.0 possesses higher probability of non-avidity to radioiodine.

Citing Articles

Redifferentiation Therapies in Thyroid Oncology: Molecular and Clinical Aspects.

Petranovic Ovcaricek P, Tuncel M, Aghaee A, Campenni A, Giovanella L J Clin Med. 2024; 13(23).

PMID: 39685478 PMC: 11642198. DOI: 10.3390/jcm13237021.

Role of [F]FDG PET/CT in the management of follicular cell-derived thyroid carcinoma.

Zajkowska K, Cegla P, Dedecjus M Cancer Imaging. 2024; 24(1):147.

PMID: 39468677 PMC: 11514821. DOI: 10.1186/s40644-024-00791-8.

[F]FDG PET/CT can trigger relevant oncological management changes leading to favorable outcome in iodine-negative thyroid cancer patients.

Zhi Y, Higuchi T, Hackenberg S, Hagen R, Stoth M, Scherzad A Endocrine. 2023; 84(2):656-662.

PMID: 38133766 PMC: 11076315. DOI: 10.1007/s12020-023-03645-8.

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer.

Petranovic Ovcaricek P, Campenni A, de Keizer B, Deandreis D, Kreissl M, Vrachimis A Cancers (Basel). 2023; 15(17).

PMID: 37686566 PMC: 10486510. DOI: 10.3390/cancers15174290.

Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance.

Hamidi S, Hofmann M, Iyer P, Cabanillas M, Hu M, Busaidy N Front Endocrinol (Lausanne). 2023; 14:1176731.

PMID: 37435488 PMC: 10331470. DOI: 10.3389/fendo.2023.1176731.

References

Rosenbaum-Krumme S, Gorges R, Bockisch A, Binse I . ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging. 2012; 39(9):1373-80. DOI: 10.1007/s00259-012-2065-4. View

Campenni A, Giovanella L, Siracusa M, Stipo M, Alibrandi A, Cucinotta M . Is malignant nodule topography an additional risk factor for metastatic disease in low-risk differentiated thyroid cancer?. Thyroid. 2014; 24(11):1607-11. DOI: 10.1089/thy.2014.0217. View

Lee J, Lee S, Lee D, Kim Y . Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients. J Nucl Med. 2013; 54(8):1230-6. DOI: 10.2967/jnumed.112.117119. View

Demers L, Spencer C . Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol (Oxf). 2003; 58(2):138-40. DOI: 10.1046/j.1365-2265.2003.01681.x. View

Wang W, Larson S, Fazzari M, Tickoo S, Kolbert K, Sgouros G . Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000; 85(3):1107-13. DOI: 10.1210/jcem.85.3.6458. View

Ruan M, Liu M, Dong Q, Chen L . Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer. J Clin Endocrinol Metab. 2015; 100(5):1771-9. DOI: 10.1210/jc.2014-3023. View

Gaertner F, Okamoto S, Shiga T, Ito Y, Uchiyama Y, Manabe O . FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well-differentiated thyroid cancer than radioiodine uptake. Clin Nucl Med. 2015; 40(5):378-83. DOI: 10.1097/RLU.0000000000000699. View

Ruan M, Shen Y, Chen L, Li M . RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma. Oncol Lett. 2013; 6(2):480-486. PMC: 3789091. DOI: 10.3892/ol.2013.1424. View

Schlumberger M . Papillary and follicular thyroid carcinoma. N Engl J Med. 1998; 338(5):297-306. DOI: 10.1056/NEJM199801293380506. View

10.

Miller M, Chen Q, Elashoff D, Abemayor E, St John M . Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review. Head Neck. 2010; 33(4):562-5. DOI: 10.1002/hed.21492. View

11.

Makeieff M, Burcia V, Raingeard I, Eberle M, Cartier C, Garrel R . Positron emission tomography-computed tomography evaluation for recurrent differentiated thyroid carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis. 2012; 129(5):251-6. DOI: 10.1016/j.anorl.2012.01.003. View

12.

Grabellus F, Nagarajah J, Bockisch A, Schmid K, Sheu S . Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med. 2012; 37(2):121-7. DOI: 10.1097/RLU.0b013e3182393599. View

13.

Robbins R, Wan Q, Grewal R, Reibke R, Gonen M, Strauss H . Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2005; 91(2):498-505. DOI: 10.1210/jc.2005-1534. View

14.

Cheng L, Liu M, Ruan M, Chen L . Challenges and strategies on radioiodine treatment for differentiated thyroid carcinoma. Hell J Nucl Med. 2016; 19(1):23-32. DOI: 10.1967/s002449910334. View

15.

Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R . Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients. Clin Nucl Med. 2014; 40(2):111-5. DOI: 10.1097/RLU.0000000000000621. View

16.

Oler G, Ebina K, Michaluart Jr P, Kimura E, Cerutti J . Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol (Oxf). 2005; 62(4):509-11. DOI: 10.1111/j.1365-2265.2005.02235.x. View

17.

Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S . Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med. 2006; 47(4):616-24. View

18.

Lassmann M, Luster M, Hanscheid H, Reiners C . Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med. 2004; 45(4):619-25. View

19.

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View

20.

Adams M, Turkington T, Wilson J, Wong T . A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010; 195(2):310-20. DOI: 10.2214/AJR.10.4923. View